Chris Womack
YOU?
Author Swipe
View article: Supplementary Materials and Methods from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Materials and Methods from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 56KB, Supplementary methods detailing Relative peptide quantification by selected reaction monitoring (SRM)using mass spectrometry
View article: Data from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Data from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressi…
View article: Supplementary Figure Legends from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 71KB
View article: Supplementary Materials and Methods from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Materials and Methods from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 56KB, Supplementary methods detailing Relative peptide quantification by selected reaction monitoring (SRM)using mass spectrometry
View article: Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 464KB, Supplementary Figure 1: Inhibition of AR transcripts with AZD3514 treated LNCaPs in steroid free media and the timecourse of AZD3514 effects in the presence and absence of DHT. Supplementary Figure 2: Effect of AZD3514 on grow…
View article: Data from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Data from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressi…
View article: Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 464KB, Supplementary Figure 1: Inhibition of AR transcripts with AZD3514 treated LNCaPs in steroid free media and the timecourse of AZD3514 effects in the presence and absence of DHT. Supplementary Figure 2: Effect of AZD3514 on grow…
View article: Supplementary Tables 1-4 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Tables 1-4 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 329KB, Supplementary Table 1: TSQ Vantage mass spectrometry instrument settings. Supplementary Table 2: 4000 QTRAP mass spectrometry instrument settings. Supplementary Table 3: The half-life of AR for the first 6 hours following trea…
View article: Supplementary Tables 1-4 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Tables 1-4 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 329KB, Supplementary Table 1: TSQ Vantage mass spectrometry instrument settings. Supplementary Table 2: 4000 QTRAP mass spectrometry instrument settings. Supplementary Table 3: The half-life of AR for the first 6 hours following trea…
View article: Supplementary Figure Legends from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 71KB
View article: Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for whole human diagnostic cancer specimens.
View article: Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 129K, Reduced nuclear PTEN in SCC compared with AC (TMA Set 2).
View article: Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).
View article: Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 129K, Reduced nuclear PTEN in SCC compared with AC (TMA Set 2).
View article: Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 2029K, Examples of tumour types classified as predominantly tumour vessel or stromal vessel phenotypes from TMA cores.
View article: Data from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Data from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
Purpose: The phosphoinositide 3-kinase (PI3K) pathway is a major oncogenic signaling pathway and an attractive target for therapeutic intervention. Signaling through the PI3K pathway is moderated by the tumor suppressor PTEN, which …
View article: Supplementary Figures 1 and 2 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Supplementary Figures 1 and 2 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 Open
Patient STAT reductions and reproducibility of replicates
View article: Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 211K, Additional biomarker responses to DC101 in Calu-3 xenograft model.
View article: Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs. However, VEGF receptor (VEGFR) expression in human cancers, particularly th…
View article: Supplementary Table 3 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Supplementary Table 3 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 Open
Gene expression signatures used in Figure 1
View article: Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).
View article: Supplementary Methods from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Supplementary Methods from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 Open
Gating and antibodies for flow cytometry and CyTOF
View article: Supplementary Figures 10 and 11 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Supplementary Figures 10 and 11 from <i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 Open
Cytokine, T, and NK cell changes in CT26 tumors
View article: Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 22K
View article: Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for human cancer specimens employed in tissue microarray analyses.
View article: Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 90K, TaqMan Fluidigm probe sets.
View article: Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 121K, Intra-sample distribution of the two phenotypes within diagnostic samples and concordance with the phenotype classifications for matched TMA cores.
View article: Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).
View article: Supplementary Table 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Table 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 78K, Mutation status of AZ samples acquired through Liverpool Heart and Chest Hospital.
View article: Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 260K, H+E comparison of typical morphologies of pancreatic neuroendocrine cancer and pancreatic adenocarcinoma and additional biomarker analyses of the two phenotypes.